Cara Care has been acquired by Mahana Therapeutics

February 2024 — Mahana Therapeutics Inc., renowned for its pioneering digital treatments targeting chronic health issues, has recently finalized the acquisition of Cara Care (HiDoc Technologies GmbH). Cara Care stands out as a premier digital health platform and an official digital health application (DiGA) dedicated to enhancing gut health. This acquisition, supported by key investors Lux Capital and Jazz Ventures Partners, perfectly aligns with Mahana’s expansion strategy.

Cara Care is the leading German digestive health therapeutic solution that combines both, mental and nutritional therapy options. With its MDR Class I approved IBS solution which is fully reimbursed by all German SHI and DiGA-certified providers, the company stands as a pioneer and demonstrates growth in an underserved sector. Venture capital-backed with lead investors Atlantic Labs, Asabys Partners, Johnson & Johnson Innovation & Dr. Schar, Cara Care was able to build a product pipeline not only for IBS but also heartburn, dyspepsia and IBD.

Mahana Therapeutics is a US-based company that stands at the forefront of digital health innovation, specializing in the development of digital therapeutics for chronic health conditions. With a focus on cognitive and behavioral therapy-based solutions, Mahana has secured FDA clearance for its pioneering IBS treatment program Mahana IBS, demonstrating its commitment to clinically validated and regulatory-compliant healthcare interventions. Backed by significant venture capital and strategic partnerships, Mahana Therapeutics is expanding its treatment portfolio to address a wider range of chronic conditions, leveraging technology to improve patient outcomes and accessibility to care.

Our role in the transaction

Oaklins’ team in Germany provided comprehensive advisory services to the private shareholder of Cara Care in this transaction.